Non-invasive structural tissue analysis for low-cost, highly accurate, safe and rapid cancer diagnosis.

全球约50%的人口将在其一生中患上癌症[世卫组织，2022年]。乳腺癌是最常见的形式，全球每年有685,000人死亡[世卫组织，2021年]。癌症的经济成本是巨大的，据最新估计，全球经济成本约占全球GDP的1.5%(7350亿GB)。在英国，2020年癌症的经济成本估计为76亿GB/年，预计还会随着人口老龄化而上升。癌症的早期诊断是提高生存机会的关键。此外，监测治疗效果对健康结果至关重要，也是确定/论证/衡量治疗效果的关键。随着全球人口的增长，癌症病例数量预计将增加，从而推动对改进诊断的需求。目前最先进的癌症诊断技术仅限于特异性和选择性有限的侵入性技术或昂贵的非侵入性技术。侵入性和非侵入性技术都需要预约医院，这限制了筛查程序的采用。因此，对改进癌症诊断的需求迅速增长。EosDx正与基尔大学合作开发和优化Nista，这是一种非侵入性结构组织分析设备，提供安全和准确的癌症诊断和监测。该联盟在X射线衍射、结构结晶学和组织分析方面拥有领先的专业知识，并曾在诊断领域开发出改变游戏规则的技术。在这个项目中，该联盟将专注于优化Nista诊断设备，使其能够通过X射线衍射成像进行癌症诊断。Nista诊断技术比目前最先进的技术有了很大的改进，因为它能够实现无症状、快速、安全、非侵入性和高度准确的癌症诊断。这一高度创新的项目旨在从英国内部扩大诊断部门，推动一个全新的行业细分市场的增长

~50% of the global population will develop cancer in their lifetime \[WHO,2022\]. Breast cancer is the most common form, with 685,000 deaths/year globally \[WHO,2021\]. The economic cost of cancer is significant with the last estimate of the global economic cost at ~1.5% of Global GDP(£735bn). In the UK, the economic cost of cancer was estimated at £7.6bn/year in 2020 and is expected to rise with the ageing population \[PharmaTimes,2020\]. Early diagnosis of cancer is key to improving chances of survival. Furthermore, monitoring the efficacy of treatment is vital to health outcomes, as well as identifying/demonstrating/measuring treatment efficacy.As the global population rises, the number of cancer cases is expected to increase, driving the need for improved diagnostics. Current-state-of-the-art cancer diagnostics are limited to either invasive techniques that have limited specificity and selectivity or non-invasive techniques that are highly expensive. Both invasive and non-invasive techniques require a hospital appointment, limiting the uptake of screening programs. Hence, there is a rapidly growing need for improved cancer diagnostics.EosDx in collaboration with Keele University is looking to develop and optimise 'NISTA', a non-invasive structural tissue analysis device offering safe and accurate cancer diagnosis and monitoring. The consortium possesses leading expertise in x-ray diffraction, structural crystallography and tissue analysis and has previously developed game-changing technologies within the diagnostic sector.In this project, the consortium will focus on optimising the NISTA diagnostic device, enabling cancer diagnosis through X-ray diffraction imaging. The NISTA diagnostic improves significantly over current-state-of-the-art as it enables pre-symptomatic, rapid, safe, non-invasive and highly accurate cancer diagnostics.This highly innovative project aims to expand the diagnostics sector from within the UK, driving the growth of a completely new industry sub-segment